登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C36H39NO5 · HCl
化学文摘社编号:
分子量:
602.16
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
Cinaciguat hydrochloride, ≥98% (HPLC)
SMILES string
OC(C(C=C1)=CC=C1CN(CCCCC(O)=O)CCC2=CC=CC=C2OCC3=CC=C(CCC4=CC=CC=C4)C=C3)=O.[H]Cl
InChI
1S/C36H39NO5.ClH/c38-35(39)12-6-7-24-37(26-30-19-21-33(22-20-30)36(40)41)25-23-32-10-4-5-11-34(32)42-27-31-17-15-29(16-18-31)14-13-28-8-2-1-3-9-28;/h1-5,8-11,15-22H,6-7,12-14,23-27H2,(H,38,39)(H,40,41);1H
InChI key
LLHMBJOVHATVSP-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 10 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Cinaciguat activates sGC (soluble guanylate cyclase) independently of NO.
Cinaciguat activates sGC (soluble guanylate cyclase) independently of NO. Cinaciguat binds to sGC′s NO-sensory H-NOX domain when it is heme-depleted. Also, the compound Cinaciguat protects sGC from oxidation-induced ubiquitin-triggered degradation.
Cinaciguat, also known as BAY 58-2667, is a novel activator of guanylate cyclase. It is used in the treatment of acute decompensated heart failure (ADHF). It has been reported that cinaciguat possesses cardiovascular effects.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Wolfgang Mueck et al.
Clinical pharmacokinetics, 49(2), 119-129 (2010-01-14)
Cinaciguat (BAY 58-2667) is a novel soluble guanylate cyclase activator in clinical development for the treatment of acute decompensated heart failure (ADHF). In patients with ADHF, intravenously administered cinaciguat results in potent unloading of the heart with arterial vasodilation. The
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持